New Blood Test Offers Potential for Faster, Targeted Treatment of Non-Small-Cell Lung Cancer (IMAGE)

Elsevier Health Sciences

New Blood Test Offers Potential for Faster, Targeted Treatment of Non-Small-Cell Lung Cancer

Caption

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive tissue biopsy, which may often be unnecessary and delays treatment. A report in The Journal of Molecular Diagnostics describes a new blood test that can accurately and quickly identify genetic mutations associated with NSCLC, allowing clinicians to make earlier, individualized treatment choices -- a step forward in personalized cancer treatment.

Credit

Biodesix, Inc.

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.